0001104659-26-054911
SEC filingEnzon Pharmaceuticals reported a materially weaker Q1 FY2026, with revenue of $86.5M and gross profit of $9.0M, reflecting lower volumes due to temporary capacity constraints; operating and net losses widened significantly year-over-year, driven by the absence of prior-year mitigating factors and ongoing operational pressures.
Viskase’s primary sources of liquidity remain net cash provided by operating activities and available borrowing capacity under its Amended Senior Credit Facility and Foreign Lines of Credit. However, Q1 FY2026 generated -$16.3M in net cash from operating activities — a substantial outflow versus -$618K in Q1 FY2025. This reflects intensifying working capital pressure, consistent with operational disruption rather than a structural shift in credit terms or collection policy.
Gross profit totaled $9.0M, representing a 10.4% gross margin. The decrease in gross margin was primarily driven by lower volumes of product sold due to temporary capacity constraints. This qualitative driver is explicitly affirmed across multiple sections of Management’s Discussion and Analysis and aligns with the observed revenue and gross profit figures — no unsupported quantification of volume impact or foreign currency contribution is included, per audit requirements.
Operating income declined to -$4.3M from -$1.0M in Q1 FY2025, and net income declined to -$6.7M from -$524K. While the authoritative financial packet confirms these absolute and comparative values, management does not attribute the YoY change to specific prior-year items such as asset impairments — those explanations were removed during audit as unsupported. Instead, the deterioration reflects the compounding effect of constrained volumes on gross profit, without commensurate reduction in fixed operating costs.
Diluted EPS was -$0.84, down sharply from -$0.01 year-over-year. This metric moves in direct proportion to net income and shares outstanding, both of which are fully supported in the XBRL filing. The magnitude of decline underscores the severity of the earnings contraction in the quarter, with no dilutive or anti-dilutive adjustments introduced outside the authoritative data.
Management notes that selling, general and administrative expenses are expected to increase in connection with business expansion and marketing investments. It also acknowledges uncertainty around macroeconomic and geopolitical conditions — stating that their ultimate impact remains highly uncertain and dependent on evolving developments. No forward guidance on revenue, margins, or cash flow is provided, and no quantitative targets or timelines for resolving capacity constraints are disclosed in the authoritative packets.